Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Heidi S. Phillips is active.

Publication


Featured researches published by Heidi S. Phillips.


Neuron | 2000

Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system

Asa Abeliovich; Yvonne Schmitz; Isabel Fariñas; Dl Choi-Lundberg; Wei Hsien Ho; Pablo E. Castillo; Natasha Shinsky; José Manuel García Verdugo; Mark Armanini; Anne M. Ryan; Mary Hynes; Heidi S. Phillips; David Sulzer; Arnon Rosenthal

alpha-Synuclein (alpha-Syn) is a 14 kDa protein of unknown function that has been implicated in the pathophysiology of Parkinsons disease (PD). Here, we show that alpha-Syn-/- mice are viable and fertile, exhibit intact brain architecture, and possess a normal complement of dopaminergic cell bodies, fibers, and synapses. Nigrostriatal terminals of alpha-Syn-/- mice display a standard pattern of dopamine (DA) discharge and reuptake in response to simple electrical stimulation. However, they exhibit an increased release with paired stimuli that can be mimicked by elevated Ca2+. Concurrent with the altered DA release, alpha-Syn-/- mice display a reduction in striatal DA and an attenuation of DA-dependent locomotor response to amphetamine. These findings support the hypothesis that alpha-Syn is an essential presynaptic, activity-dependent negative regulator of DA neurotransmission.


Cancer Cell | 2010

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

Houtan Noushmehr; Daniel J. Weisenberger; Kristin Diefes; Heidi S. Phillips; Kanan Pujara; Benjamin P. Berman; Fei Pan; Christopher E. Pelloski; Erik P. Sulman; Krishna P. Bhat; Roel G.W. Verhaak; Katherine A. Hoadley; D. Neil Hayes; Charles M. Perou; Heather K. Schmidt; Li Ding; Richard Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie Cope; Jonathan D. Buckley; James G. Herman; Stephen B. Baylin; Peter W. Laird; Kenneth D. Aldape

We have profiled promoter DNA methylation alterations in 272 glioblastoma tumors in the context of The Cancer Genome Atlas (TCGA). We found that a distinct subset of samples displays concerted hypermethylation at a large number of loci, indicating the existence of a glioma-CpG island methylator phenotype (G-CIMP). We validated G-CIMP in a set of non-TCGA glioblastomas and low-grade gliomas. G-CIMP tumors belong to the proneural subgroup, are more prevalent among lower-grade gliomas, display distinct copy-number alterations, and are tightly associated with IDH1 somatic mutations. Patients with G-CIMP tumors are younger at the time of diagnosis and experience significantly improved outcome. These findings identify G-CIMP as a distinct subset of human gliomas on molecular and clinical grounds.


Cell | 1994

Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons

Craig Crowley; Susan D. Spencer; Merry Nishimura; Karen S. Chen; Sharon Pitts-Meek; Mark P. Armaninl; Lanway H. Ling; Stephen B. McMahon; David L. Shelton; Arthur D. Levinson; Heidi S. Phillips

Homologous recombination was utilized to generate mice with a deletion in the coding sequence of the nerve growth factor (NGF) gene. Animals homozygous for NGF disruption failed to respond to noxious mechanical stimuli, and histological analysis revealed profound cell loss in both sensory and sympathetic ganglia. Within dorsal root ganglia, effects of the mutation appeared to be restricted to small and medium peptidergic neurons. These observations confirm the critical dependence of sensory and sympathetic neurons on NGF and demonstrate that other neurotrophins are not able to compensate for the loss of NGF action on these cells. Examination of the central nervous system revealed that, in marked contrast with neurons of sensory and sympathetic ganglia, basal forebrain cholinergic neurons differentiate and continue to express phenotypic markers for the life span of the null mutant mice. Thus, differentiation and initial survival of central NGF-responsive neurons can occur in the absence of NGF.


Neuron | 1991

BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease

Heidi S. Phillips; Jeanne M. Hains; Mark Armanini; Gary R. Laramee; Steven A. Johnson; John W. Winslow

In recent years, nerve growth factor (NGF) has gained attention as a potential therapeutic agent for Alzheimers disease (AD). To study the expression of NGF and its homologs, brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT-3), postmortem samples of hippocampus from AD and control donors were examined by in situ hybridization. Hybridization signal for BDNF, but not NGF or NT-3, was decreased in samples of hippocampus from donors with AD. Decreased transcript abundance of BDNF mRNA in hippocampi of individuals with AD was verified by an RNAase protection assay. These results suggest the possibility that decreased expression of BDNF may contribute to the progression of cell death in AD.


Neuron | 1994

Expression and coexpression of Trk receptors in subpopulations of adult primary sensory neurons projecting to identified peripheral targets.

Stephen B. McMahon; Mark Armanini; Lanway H. Ling; Heidi S. Phillips

To determine whether neurotrophins act on functionally distinct populations of adult sensory neurons, the distributions of mRNAs for TrkA and tyrosine kinase-containing isoforms of TrkB and TrkC were determined in rat DRG neurons projecting to different peripheral targets. Whereas trkA was expressed by a very high percentage of visceral afferents, trkC was expressed frequently only in muscle afferents. Among cutaneous afferents, the size distributions for trkA- and trkC-positive cells showed little overlap. The percentages and size distributions of cells labeled for the trks argue strongly that almost all trkB-expressing cells must also express trkA or trkC. These results indicate that NGF and NT-3 act on functionally distinct populations of adult sensory neurons and suggest that a sizeable number of small DRG neurons may not respond to neurotrophins via a known Trk in the adult rat.


Neuron | 1998

GFRα1 Is an Essential Receptor Component for GDNF in the Developing Nervous System and Kidney

Grace Cacalano; Isabel Fariñas; Li-Chong Wang; Kelly E. Hagler; Alison Forgie; Mark W. Moore; Mark Armanini; Heidi S. Phillips; Anne M. Ryan; Louis F. Reichardt; Mary Hynes; Alun M. Davies; Arnon Rosenthal

Glial cell line-derived neurotrophic factor (GDNF) is a distant member of the TGFbeta protein family that is essential for neuronal survival and renal morphogenesis. We show that mice who are deficient in the glycosyl-phosphatidyl inositol (GPI) -linked protein GFRalpha1 (GDNFRalpha) display deficits in the kidneys, the enteric nervous system, and spinal motor and sensory neurons that are strikingly similar to those of the GDNF- and Ret-deficient mice. GFRalpha1-deficient dopaminergic and nodose sensory ganglia neurons no longer respond to GDNF or to the structurally related protein neurturin (NTN) but can be rescued when exposed to GDNF or neurturin in the presence of soluble GFRalpha1. In contrast, GFRalpha1-deficient submandibular parasympathetic neurons retain normal response to these two factors. Taken together with the available genetic and biochemical data, these findings support the idea that GFRalpha1 and the transmembrane tyrosine kinase Ret are both necessary receptor components for GDNF in the developing kidney and nervous system, and that GDNF and neurturin can mediate some of their activities through a second receptor.


Neuron | 1998

Persephin, a Novel Neurotrophic Factor Related to GDNF and Neurturin

Jeffrey Milbrandt; Frederic J. de Sauvage; Timothy J. Fahrner; Robert H. Baloh; Melanie L. Leitner; Malú G. Tansey; Patricia A. Lampe; Robert O. Heuckeroth; Paul T. Kotzbauer; Kelli S. Simburger; Judith P. Golden; Jamie A. Davies; Richard Vejsada; Ann C. Kato; Mary Hynes; Daniel Sherman; Merry Nishimura; Li-Chong Wang; Richard Vandlen; Barbara Moffat; Robert D. Klein; Kris Poulsen; Christa L. Gray; Alain Garces; Christopher E. Henderson; Heidi S. Phillips; Eugene M. Johnson

A novel neurotrophic factor named Persephin that is approximately 40% identical to glial cell line-derived neurotrophic factor (GDNF) and neurturin (NTN) has been identified using degenerate PCR. Persephin, like GDNF and NTN, promotes the survival of ventral midbrain dopaminergic neurons in culture and prevents their degeneration after 6-hydroxydopamine treatment in vivo. Persephin also supports the survival of motor neurons in culture and in vivo after sciatic nerve axotomy and, like GDNF, promotes ureteric bud branching. However, in contrast to GDNF and NTN, persephin does not support any of the peripheral neurons that were examined. Fibroblasts transfected with Ret and one of the coreceptors GFRalpha-1 or GFRalpha-2 do not respond to persephin, suggesting that persephin utilizes additional, or different, receptor components than GDNF and NTN.


Nature | 1997

A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor.

Robert D. Klein; Daniel Sherman; Wei-Hsien Ho; Donna M. Stone; Gregory L. Bennett; Barbara Moffat; Richard Vandlen; Laura Simmons; Qimin Gu; Jo-Anne Hongo; Brigitte Devaux; Kris Poulsen; Mark Armanini; Chika Nozaki; Naoya Asai; Audrey Goddard; Heidi S. Phillips; Chris E. Henderson; Masahide Takahashi; Arnon Rosenthal

Glial-cell-line-derived neurotrophic factor (GDNF) and neurturin (NTN) are two structurally related, potent survival factors for sympathetic, sensory and central nervous system neurons. GDNF mediates its actions through a multicomponent receptor system composed of a ligand-binding glycosyl-phosphatidylinositol (GPI)-linked protein (designated GDNFR-α) and the transmembrane protein tyrosine kinase Ret. In contrast, the mechanism by which the NTN signal is transmitted is not well understood. Here we describe the identification and tissue distribution of a GPI-linked protein (designated NTNR-α) that is structurally related to GDNFR-α. We further demonstrate that NTNR-α binds NTN (Kd ∼ 10 pM) but not GDNF with high affinity; that GDNFR-α binds to GDNF but not NTN with high affinity; and that cellular responses to NTN require the presence of NTNR-α. Finally, we show that NTN, in the presence of NTNR-α, induces tyrosine-phosphorylation of Ret, and that NTN, NTNR-α and Ret form a physical complex on the cell surface. These findings identify Ret and NTNR-α as signalling and ligand-binding components, respectively, of a receptor for NTN and define a novel family of receptors for neurotrophic and differentiation factors composed of a shared transmembrane protein tyrosine kinase and a ligand-specific GPI-linked protein.


Cancer Cell | 2010

A Hierarchy of Self-Renewing Tumor-Initiating Cell Types in Glioblastoma

Ruihuan Chen; Merry Nishimura; Stephanie M. Bumbaca; Samir Kharbanda; William F. Forrest; Ian Kasman; Joan M. Greve; Robert Soriano; Laurie L. Gilmour; Celina Sanchez Rivers; Zora Modrusan; Serban Nacu; Steve Guerrero; Kyle A. Edgar; Jeffrey Wallin; Katrin Lamszus; Manfred Westphal; Susanne Heim; C. David James; Scott R. VandenBerg; Joseph F. Costello; Scott Moorefield; Cynthia Cowdrey; Michael D. Prados; Heidi S. Phillips

The neural stem cell marker CD133 is reported to identify cells within glioblastoma (GBM) that can initiate neurosphere growth and tumor formation; however, instances of CD133(-) cells exhibiting similar properties have also been reported. Here, we show that some PTEN-deficient GBM tumors produce a series of CD133(+) and CD133(-) self-renewing tumor-initiating cell types and provide evidence that these cell types constitute a lineage hierarchy. Our results show that the capacities for self-renewal and tumor initiation in GBM need not be restricted to a uniform population of stemlike cells, but can be shared by a lineage of self-renewing cell types expressing a range of markers of forebrain lineage.


Neuro-oncology | 2010

A multigene predictor of outcome in glioblastoma

Howard Colman; Li Zhang; Erik P. Sulman; J. Matthew McDonald; Nasrin Latif Shooshtari; Andreana L. Rivera; Sonya Popoff; Catherine L. Nutt; David N. Louis; J. Gregory Cairncross; Mark R. Gilbert; Heidi S. Phillips; Minesh P. Mehta; Arnab Chakravarti; Christopher E. Pelloski; Krishna P. Bhat; Burt G. Feuerstein; Robert B. Jenkins; Kenneth D. Aldape

Only a subset of patients with newly diagnosed glioblastoma (GBM) exhibit a response to standard therapy. To date, a biomarker panel with predictive power to distinguish treatment sensitive from treatment refractory GBM tumors does not exist. An analysis was performed using GBM microarray data from 4 independent data sets. An examination of the genes consistently associated with patient outcome, revealed a consensus 38-gene survival set. Worse outcome was associated with increased expression of genes associated with mesenchymal differentiation and angiogenesis. Application to formalin fixed-paraffin embedded (FFPE) samples using real-time reverse-transcriptase polymerase chain reaction assays resulted in a 9-gene subset which appeared robust in these samples. This 9-gene set was then validated in an additional independent sample set. Multivariate analysis confirmed that the 9-gene set was an independent predictor of outcome after adjusting for clinical factors and methylation of the methyl-guanine methyltransferase promoter. The 9-gene profile was also positively associated with markers of glioma stem-like cells, including CD133 and nestin. In sum, a multigene predictor of outcome in glioblastoma was identified which appears applicable to routinely processed FFPE samples. The profile has potential clinical application both for optimization of therapy in GBM and for the identification of novel therapies targeting tumors refractory to standard therapy.

Collaboration


Dive into the Heidi S. Phillips's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge